<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Leukocytes play an important role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> development </plain></SENT>
<SENT sid="1" pm="."><plain>However, the impact of chemotherapy-associated <z:hpo ids='HP_0001875'>neutropenia</z:hpo>/<z:hpo ids='HP_0001888'>lymphopenia</z:hpo> on the prognosis of adjuvant chemotherapy is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we aimed to explore the impact of chemotherapy-associated neutrophil/lymphocyte counts on prognosis of adjuvant chemotherapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and the risk factors for developing <z:hpo ids='HP_0001875'>neutropenia</z:hpo>/<z:hpo ids='HP_0001888'>lymphopenia</z:hpo> which showed impact on the prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> receiving adjuvant chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: From February 2003 to January 2011, 243 stage II and III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients receiving adjuvant chemotherapy were enrolled in this retrospective study </plain></SENT>
<SENT sid="4" pm="."><plain>The associations between neutrophil/ lymphocyte counts and disease free survival (DFS)/overall survival (OS) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and the risk factors for <z:hpo ids='HP_0001875'>neutropenia</z:hpo>/<z:hpo ids='HP_0001888'>lymphopenia</z:hpo> were investigated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: No association of chemotherapy-associated neutrophil counts and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> recurrence (AUC = 0.474, P = 0.534), <z:hpo ids='HP_0011420'>death</z:hpo> (AUC = 0.449, P = 0.249) was found by ROC analysis </plain></SENT>
<SENT sid="6" pm="."><plain>However, the chemotherapy-associated lymphocyte counts could significantly affect <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> recurrence (AUC = 0.634, P = 0.001), or <z:hpo ids='HP_0011420'>death</z:hpo>(AUC���= 0.607, P = 0.015), with a optimized cut-off of 0.66 × 109/L for recurrence, and 0.91 × 109/L for <z:hpo ids='HP_0011420'>death</z:hpo>, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Kaplan-Meier method showed chemotherapy-associated <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.66 × 109/L was associated with shorter DFS (P &lt; 0.0001), and chemotherapy-associated <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.91 × 109/L was associated with shorter OS (P��= 0.003) </plain></SENT>
<SENT sid="8" pm="."><plain>Cox regression model showed chemotherapy-associated <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.66 × 109/L was the independent prognostic factor for DFS (HR, 3.521; 95%CI = 1.703-7.282), and chemotherapy-associated <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.91 × 109/L was the independent prognostic factor for OS (HR, 2.083; 95% CI = 1.103-3.936) </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate logistic regression showed the risk of developing chemotherapy-associated <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.66 × 109/L was found in those with pretreatment CEA ≥10 ng ml-1 (OR, 3.338; 95% CI = 1.523-7.315), and the risk of developing chemotherapy-associated <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.91 × 109/L was found in those with age &gt;60 years (OR, 2.872; 95% CI = 1.344-6.136) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Chemotherapy-associated <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.66 × 109/L /0.91 × 109/L has a significant impact on the prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> receiving adjuvant chemotherapy </plain></SENT>
<SENT sid="11" pm="."><plain>Pretreatment CEA ≥10 ng ml-1 is the independent risk factor for developing <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.66 × 109/L, and age &gt;60 years is the independent risk factor for developing <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> &lt;0.91 × 109/L during adjuvant chemotherapy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>